Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
2 hedge funds and large institutions have $12.7M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
37% less capital invested
Capital invested by funds: $20M → $12.7M (-$7.33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$909K |
| 2 |
FIA
FNY Investment Advisers
New York
|
+$20.9K |
Top Sellers
BHVN Hedge Fund Activity: Q2 2025 in Review
2 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2025, worth a combined $12.7M — down 37% from $20M a quarter earlier.
Fund positioning in BHVN was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Knoll Capital Management, adding an estimated $909K.
- 2 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $12.7M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2025, down 37% quarter-over-quarter.
- 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2025 and 0 closed out.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2025 was Knoll Capital Management, an estimated $909K added.
Based on aggregated 13F filings for Q2 2025.